Clin Asst Prof Chan Junjie Jack

Dr Jack Chan is a Senior Consultant Medical Oncologist who practises at NCCS and KKWCH, subspecialising in gynaecological and breast cancers. As an advocate for a personalised approach to cancer care, Dr Chan strives to support patients and their families through the cancer journey by addressing patients' medical needs and quality of life.

Dr Chan concurrently holds the appointment of Chief Quality Officer at NCCS, overseeing Patient Safety and Quality, Patient Experience, and Appropriate and Value-Based Care.

Dr Chan’s research interests are clinical trials in women’s cancers, being the Principal Investigator of investigator-initiated and industry-sponsored trials. He sits on the steering committee of several international randomised phase III trials.

Dr Chan is active in medical education as well as in professional bodies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He serves on the Japanese Society of Medical Oncology’s International Steering Committee, and sat on the European Society of Medical Oncology Congress’s Scientific Committee and Asian Society of Gynecologic Oncology Meeting’s International Scientific Committee in 2024.

Dr Chan has received accolades for his clinical, education and administrative work including Singapore Health Quality Service Awards, Outstanding Faculty Awards and the Commendation Medal (COVID-19).

• Fellow of Academy of Medicine Singapore, Chapter of Medical Oncologists, College of Physicians, 2018
• Member of Royal College of Physicians (UK); Master of Medicine (Internal Medicine) (Singapore), 2012
• Bachelor of Medicine and Bachelor of Surgery, 2008

• Member, Ministry of Health Singapore’s Ensure Safer Systems (ESS) Working Committee 2026-2028
• Vice President, Gynecologic Cancer Group Singapore 2025-2026
• Co-opted Board Member, Chapter of Medical Oncology, College of Physicians, Academy of Medicine, Singapore 2023-2025
• Member, Japanese Society of Medical Oncology’s International Steering Committee 2023-2028
• Member, European Society of Medical Oncology Congress 2024 Scientific Committee
• Member, Asian Society of Gynecologic Oncology 2024 Meeting International Scientific Committee
• Chairperson, Resource Optimisation Workgroup, NCCS 2022-2024
• Lead, Epidemiology Team, NCCS 2020-2021
• Co-Chairperson, Breast Cancer Awareness Month Committee, NCCS 2018-2024
• Clinical Core Faculty Member, SingHealth Medical Oncology Residency Programme 2018-2024  

• The Commendation Medal (COVID-19) 2023 
• COVID-19 Resilience Medal 2023 
• Singapore Health Quality Service Award (Star) 2022 
• SingHealth Family Target Zero Harm Team Award 2021
• Singapore Health Quality Service Award (Hero) 2021 
• Residency in SingHealth Excels Outstanding Faculty Award 2020, 2025
• Singapore Health Quality Service Award (Gold) 2020 
• SingHealth Health Manpower Development Plan Award 2019 
• Singapore Health Quality Service Award (Silver) 2019

• Symbiotic-GYN-18: an interventional phase 3, open label, randomized study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with advanced or recurrent mismatch repair proficient endometrial cancer (ClinicalTrials.gov Identifier: NCT07578649) (Site Principal Investigator)
• BEHOLD-Ovarian03: A randomized, double-blind, multicenter, placebo-controlled, phase 3 study to evaluate the efficacy and safety of mocertatug rezetecan with or without bevacizumab as maintenance treatment in participants with newly diagnosed FIGO stage III/IV homologous recombination proficient ovarian, fallopian tube, or primary peritoneal cancer (ClinicalTrials.gov Identifier: NCT07694427) (National Principal Investigator)
• BEHOLD-Ovarian02: a randomized, open-label, multicenter, phase 3 study to investigate mocertatug rezetecan with bevacizumab compared with platinum doublet with bevacizumab in participants with platinum-sensitive ovarian cancer (ClinicalTrials.gov Identifier: NCT07684612) (National Principal Investigator)
• RAINFOL-03: A phase 3 randomized, open-label study of rinatabart sesutecan (Rina-S) versus treatment of investigator’s choice in patients with endometrial cancer after platinum-based chemotherapy and PD(L)-1 therapy (ClinicalTrials.gov Identifier: NCT07166094) (Site Principal Investigator)
• BLUESTAR-Endometrial01: A phase III, randomized, open-label, multicentre, global study of puxitatug samrotecan (AZD8205) monotherapy versus physician’s choice of chemotherapy in participants with B7-H4-selected advanced/metastatic endometrial cancer who progressed on or after platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy (ClinicalTrials.gov Identifier: NCT07044336) (National Principal Investigator)
• MK-5684-015/OMAHA-015: A multicenter, open-label, phase 2 basket study of MK-5684 in participants with selected solid tumors (ClinicalTrials.gov Identifier: NCT06979596) (Site Principal Investigator)
• TroFuse-033/GOG-3119/ENGOT-en29: A phase 3 randomized, open-label, multicenter study to compare the efficacy and safety of sacituzumab tirumotecan (Sac-TMT, MK-2870) in combination with pembrolizumab versus pembrolizumab alone as first-line maintenance treatment in participants with mismatch repair proficient endometrial cancer (ClinicalTrials.gov Identifier: NCT06952504) (National Principal Investigator)
• NIRVANA-1: Niraparib with bevacizumab after complete cytoreduction in patients with ovarian cancer (ClinicalTrials.gov Identifier: NCT05183984) (Site Principal Investigator)  

• Ngoi NYL, Lee J-Y, Lim D, Thian YL, Lim YW, Chan JJ, Chay WY, Zhang Z, Gopinathan A, Lim SE, Low J, Ng J, Tong P, Lee Y-J, Park J, Kim J-W, Tan TZ, Zhu J, Tai BC, Choi CH, Kim B-G, Tan DSP. Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2026; 27(2):201-211.
• Lee HY, Ong WS, Tan JYT, Ma J, Zhang Z, Tan SY, Yang GM, Teo I, Goh WL, Tan MMZL, Yap YS, Chan JJ, Tan RSYC, Tan WM, Lim E, Sivaraj H, Beh SY, Soh LT, Chay WY, Dent R, Kanesvaran R, Wong M, Tan BKT, Wong FY, Tan KMV, Tan TJ. Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers – PreSCella study. NPJ Breast Cancer 2026; 12(1):32.
• Lee HY, Shih V, Chan JJ, Liong SZ, Tan RSYC, Ma J, Chua BJG, Tan JZC, Lee CY, Teo WL, Tan SM, Nitar P, Yap YS, Wong M, Dent R, Wong FY, Tan TJ. Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting. Ann Acad Med Singa 2025; 54(8):458-66.
• Ng QJ, Ee TX, Goh CSY, Lee SH, Low JEH, Lin J, Phoon JWL, Chan JJ, Chin FHX. Oncofertility care and fertility preservation in gynaecological cancer: experience from Singapore's largest tertiary centre. Singapore Med J 2025: 10.4103/singaporemedj.SMJ-2024-094.
• Ang DJM, Bok KX, Wong SL, Li Y, Wong A, Yeo YC, Wang J, Aggarwal IM, Chan JJ. Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus independent gastric-type adenocarcinoma of cervix: The Singapore experience. Gynecol Oncol Rep 2025; 58:101709.
• Tan JZC, Chan JJ, Dent RA, Tan TJ. Early triple-negative breast cancer: systemic therapy. In: Cardoso F, Tjan-Heijnen V, Božović-Spasojević I, Vaz Batista M, editors. Breast Cancer: Essentials for Clinicians Second Edition. Lugano, Switzerland: ESMO Press; 2024. p. 41-6.
• Ang DJM, Chan JJ. Evolving standards and future directions for systemic therapies in cervical cancer. J Gynecol Oncol 2024; 35(2):e65 e65.
• Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer 2023; 9(1):74.
• Loo SY, Toh LP, Xie WH, Pathak E, Tan W, Ma S, Lee MY, Shatishwaran S, JZZ Yeo, Yuan J, Ho YY, EKL Peh, Muniandy M, Torta F, Chan J, Tan T, Sim YR, Tan V, Tan B, Madhukumar P, Yong WS, Ong KW, Wong CY, Tan PH, Yap YS, Deng LW, Dent R, Foo R, Wenk MR, Lee SC, Ho YS, Lim EH. Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Sci Adv 2021; 7(41):eabh2443.
• Tan DSP, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. J Gynecol Oncol 2021; 32(2):e27.
• Kwek JW, Chan JJ, Kanesvaran R, Wang MLC, Neo PSH, Chia CS, Tham CK, Chew LST, Tan HK, Yap SP, Dent RA, Hwang WYK, Lim ST. Early outcomes of a national cancer center’s strategy against COVID-19 executed through a disease outbreak response taskforce. JCO Oncol Practice 2021; 17(3):e343-54.
• Chan JJ, Tan TJY, Dent RA. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. Curr Opin Oncol 2020; 32(6):575-84.
• Chan JJ, Sim Y, Ow SGW, Lim JSJ, Kusumawidjaja G, Zhuang Q, Wong RX, Wong FY, Tan VKM, Tan TJY. The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocr Relat Cancer 2020; 27(9):R307-27.
• Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol 2019; 11:1758835919880429.
• Chan JJ, Tan TJY, Dent RA. Are there any clinically relevant subgroups of triple-negative breast cancer in 2018? J Oncol Pract 2018; 14(5):281-9.